ストックスクリーナーアプリを入手
2.93
4.64%
0.13
アフターアワーズ：
2.93
前日終値:
$2.80
開ける：
$2.81
24時間の取引高:
420.27K
Relative Volume:
0.34
時価総額：
$189.72M
収益：
-
当期純損益:
$-292.19M
株価収益率:
-0.6454
EPS:
-4.54
ネットキャッシュフロー:
$-208.41M
1週間 パフォーマンス:
+2.09%
1か月 パフォーマンス:
+115.44%
6か月 パフォーマンス:
+99.32%
1年 パフォーマンス:
+22.08%
1日の値動き範囲:
$2.76
$2.97
1週間の範囲:
$2.65
$3.29
52週間の値動き範囲:
$1.01
$3.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.93 | 181.30M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Stock Report: Is Zentalis Pharmaceuticals Inc currently under institutional pressureDay Trade & Smart Swing Trading Alerts - baoquankhu1.vn
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - Defense World
Dow Update: How Zentalis Pharmaceuticals Inc stock reacts to job market data2025 Technical Patterns & Verified Swing Trading Watchlist - Bộ Nội Vụ
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Yahoo Finance
Zentalis Pharma Advances Stir Market as Azenosertib Program Strengthens - timothysykes.com
Zentalis outlines 2026 milestones for azenosertib program - The Globe and Mail
Zentalis Pharmaceuticals Surges After Promising Azenosertib Developments - StocksToTrade
Trade Recap: Will Zentalis Pharmaceuticals Inc stock outperform tech sector in 20252025 Performance Recap & Long-Term Safe Investment Plans - Bộ Nội Vụ
Zentalis Pharmaceuticals Surges with Azenosertib Developments - timothysykes.com
Zentalis Pharmaceuticals, Inc. Provides Corporate Update on Azenosertib Development - TradingView — Track All Markets
Azenosertib plans at Zentalis (NASDAQ: ZNTL) with cash runway to 2027 - Stock Titan
Zentalis Pharmaceuticals Stock (ZNTL) Opinions on Azenosertib Development Update - Quiver Quantitative
Aug Weekly: Is Zentalis Pharmaceuticals Inc. stock ready for breakoutPortfolio Update Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Major Investor Makes Bold Move on Zentalis Pharmaceuticals Stock - TipRanks
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Insider Buying: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Purchases 6,459,973 Shares of Stock - MarketBeat
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m By Investing.com - Investing.com Nigeria
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonWeekly Stock Report & Real-Time Volume Triggers - Улправда
Price Action: Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Quarterly Market Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Will Zentalis Pharmaceuticals Inc. stock outperform tech sector in 2025Trade Risk Assessment & Risk Adjusted Buy and Sell Alerts - Улправда
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - Улправда
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):